Sigrid Secures $5 Million for Metabolic Health Innovation
Sigrid, a pioneering consumer health company based in Sweden, has successfully raised USD 5 million to enhance its groundbreaking work in the realm of metabolic health. This recent funding round has propelled their total capital raised to approximately USD 27 million. With participation from a broad spectrum of existing and new investors worldwide, this injection of funds highlights the robust confidence in Sigrid's clinically validated platform and its burgeoning commercial presence in the United States.
As the global focus on metabolic health intensifies, there is an increasing demand from consumers, patients, and healthcare professionals for effective, scientifically-supported solutions that significantly impact blood sugar control and weight management. One standout product, Sigrid's dietary supplement Glucose Stabiliser, is experiencing rapid adoption in direct-to-consumer channels and gaining traction within the expanding network of U.S. physicians.
In the past year alone, Glucose Stabiliser has experienced over threefold revenue growth, indicative of its strong alignment with market needs and sustained consumer engagement in a rapidly evolving product category. This performance speaks volumes about the potential of Sigrid’s offerings.
Sana Alajmovic, the Co-Founder and CEO of Sigrid, expressed, "We are witnessing a transformative change in how consumers view metabolic health. Blood sugar regulation and sustainable weight management have emerged as top priorities for many individuals. There is a rising expectation for clinically validated solutions, and our unique position with one of the leading non-systemic platform technologies allows us to meet this demand head-on. This new investment is pivotal for accelerating our expansion in the United States while also enabling the development of additional sectors powered by our innovative SiPore® technology."
Advancing Regulatory Approvals and Product Expansion
Following a successful submission for CE-mark approval within the European Union, Sigrid is progressing toward the authorization of a pioneering over-the-counter medical device aimed at supporting weight management and overall metabolic health for adults facing excess weight and elevated blood sugar levels. This initiative forms part of a broader, structured approach to lifestyle management.
At the same time, Sigrid is extending the capabilities of its SiPore® platform beyond just metabolic health. The company is opening new avenues for growth across oral care, veterinary health, and food technology. They are currently engaged in active conversations with major players in consumer health, nutrition, and pharmaceuticals, seeking partnerships that will enable global brands to utilize SiPore® technology in innovative ways, reaching millions of consumers around the globe.
Get to Know Sigrid
Sigrid is committed to reshaping the landscape of metabolic health with its unique, non-systemic, and clinically validated technologies. Backed by more than 15 years of dedicated research, Sigrid’s patented SiPore® technology operates mechanically in the gut without entering systemic circulation. This innovation paves the way for secure, scalable solutions focused on daily glucose management and weight control. Furthermore, it serves as a vital foundation for creative advancements across diverse fields, including oral health, veterinary care, and food technology.
Contact Information
For more insights into Sigrid’s innovations and their impact on health, reach out to:
Sana Alajmovic
Co-founder & CEO, Sigrid
+46 723 893 396
Frequently Asked Questions
What is the latest funding amount Sigrid has secured?
Sigrid has recently raised USD 5 million to enhance its operations and technology in metabolic health.
What products does Sigrid offer?
Sigrid offers dietary supplements including Glucose Stabiliser, which helps manage blood sugar and weight.
How has Glucose Stabiliser performed recently?
The Glucose Stabiliser has seen a remarkable revenue growth of more than threefold in the past year.
What is the role of SiPore® technology?
SiPore® technology allows for innovative solutions in metabolic health without entering the bloodstream, promoting safer usage.
How is Sigrid expanding its market reach?
Sigrid is expanding into oral care, veterinary health, and food technology, exploring partnerships globally for distribution.
